(XENE) Xenon Pharmaceuticals - Ratings and Ratios
Seizure Drugs, Pain Drugs
XENE EPS (Earnings per Share)
XENE Revenue
Description: XENE Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc (NASDAQ:XENE) is a Canadian biotechnology company with a market capitalization of approximately $2.64 billion USD. The companys stock has been volatile, with a beta of 1.165, indicating a slightly higher volatility compared to the overall market.
The stocks current price is $33.63, with a 52-week high and low of $45.74 and $28.23, respectively. The average trading volume is around 764,800 shares. To assess the stocks potential, we need to examine key performance indicators (KPIs) such as revenue growth, pipeline progress, and cash burn rate. A thorough analysis of these metrics will help determine the companys financial health and potential for future growth.
As a biotechnology company, Xenons key economic drivers include the success of its pipeline assets, particularly those in clinical development. The companys return on equity (ROE) is currently negative at -32.44%, indicating that it is not generating profits from shareholder equity. The absence of a price-to-earnings (P/E) ratio, both current and forward, suggests that the company is not yet profitable. To drive growth, Xenon will need to advance its pipeline, secure partnerships or collaborations, and manage its cash resources effectively.
A critical examination of Xenons financials and pipeline progress is necessary to determine the stocks potential. Key areas to focus on include the companys cash runway, upcoming clinical trial readouts, and potential partnerships or collaborations. By analyzing these factors, we can better understand the drivers of Xenons stock performance and identify potential opportunities or risks.
XENE Stock Overview
| Market Cap in USD | 3,023m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2014-11-05 |
XENE Stock Ratings
| Growth Rating | -15.0% |
| Fundamental | 32.0% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -24.9% |
| Analyst Rating | 4.74 of 5 |
XENE Dividends
Currently no dividends paidXENE Growth Ratios
| Growth Correlation 3m | 71.1% |
| Growth Correlation 12m | -73.4% |
| Growth Correlation 5y | 71.1% |
| CAGR 5y | -1.70% |
| CAGR/Max DD 3y | -0.04 |
| CAGR/Mean DD 3y | -0.10 |
| Sharpe Ratio 12m | 0.04 |
| Alpha | 0.06 |
| Beta | 0.773 |
| Volatility | 36.53% |
| Current Volume | 768.1k |
| Average Volume 20d | 622.8k |
| Stop Loss | 34.3 (-3.8%) |
| Signal | -1.13 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-278.2m TTM) > 0 and > 6% of Revenue (6% = 601.0k TTM) |
| FCFTA -0.27 (>2.0%) and ΔFCFTA -10.28pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 4665 % (prev 13.0k%; Δ -8287 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.34 (>3.0%) and CFO -231.4m > Net Income -278.2m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 15.14 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (79.0m) change vs 12m ago 1.65% (target <= -2.0% for YES) |
| Gross Margin 80.69% (prev 28.57%; Δ 52.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.29% (prev 0.61%; Δ 0.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' 7.67
| (A) 0.69 = (Total Current Assets 500.3m - Total Current Liabilities 33.0m) / Total Assets 674.3m |
| (B) -1.56 = Retained Earnings (Balance) -1.05b / Total Assets 674.3m |
| warn (B) unusual magnitude: -1.56 — check mapping/units |
| (C) -0.41 = EBIT TTM -318.8m / Avg Total Assets 779.1m |
| (D) 10.42 = Book Value of Equity 420.1m / Total Liabilities 40.3m |
| Total Rating: 7.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.03
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -7.25% = -3.62 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda -0.03 = -2.50 |
| 6. ROIC - WACC (= -44.11)% = -12.50 |
| 7. RoE -38.50% = -2.50 |
| 8. Rev. Trend 38.98% = 2.92 |
| 9. EPS Trend 34.59% = 1.73 |
What is the price of XENE shares?
Over the past week, the price has changed by -4.93%, over one month by -5.71%, over three months by +11.37% and over the past year by -10.81%.
Is Xenon Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XENE is around 31.35 USD . This means that XENE is currently overvalued and has a potential downside of -12.09%.
Is XENE a buy, sell or hold?
- Strong Buy: 14
- Buy: 5
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the XENE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 55 | 54.1% |
| Analysts Target Price | 55 | 54.1% |
| ValueRay Target Price | 35.1 | -1.7% |
Last update: 2025-09-08 04:55
XENE Fundamental Data Overview
CCE Cash And Equivalents = 487.5m USD (Cash And Short Term Investments, last quarter)
P/S = 403.1091
P/B = 4.7688
P/EG = -0.06
Beta = 1.172
Revenue TTM = 10.0m USD
EBIT TTM = -318.8m USD
EBITDA TTM = -316.2m USD
Long Term Debt = 7.26m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.92m USD (from shortTermDebt, last quarter)
Debt = 10.2m USD (Calculated: Short Term 2.92m + Long Term 7.26m)
Net Debt = -126.7m USD (from netDebt column, last quarter)
Enterprise Value = 2.55b USD (3.02b + Debt 10.2m - CCE 487.5m)
Interest Coverage Ratio = unknown (Ebit TTM -318.8m / Interest Expense TTM 0.0)
FCF Yield = -7.25% (FCF TTM -184.5m / Enterprise Value 2.55b)
FCF Margin = -1842 % (FCF TTM -184.5m / Revenue TTM 10.0m)
Net Margin = -2778 % (Net Income TTM -278.2m / Revenue TTM 10.0m)
Gross Margin = 80.69% ((Revenue TTM 10.0m - Cost of Revenue TTM 1.93m) / Revenue TTM)
Tobins Q-Ratio = 6.06 (Enterprise Value 2.55b / Book Value Of Equity 420.1m)
Interest Expense / Debt = 74.84% (Interest Expense 7.61m / Debt 10.2m)
Taxrate = 21.0% (US default)
NOPAT = -318.8m (EBIT -318.8m, no tax applied on loss)
Current Ratio = 15.14 (Total Current Assets 500.3m / Total Current Liabilities 33.0m)
Debt / Equity = 0.02 (Debt 10.2m / last Quarter total Stockholder Equity 634.0m)
Debt / EBITDA = -0.03 (Net Debt -126.7m / EBITDA -316.2m)
Debt / FCF = -0.06 (Debt 10.2m / FCF TTM -184.5m)
Total Stockholder Equity = 722.7m (last 4 quarters mean)
RoA = -41.26% (Net Income -278.2m, Total Assets 674.3m )
RoE = -38.50% (Net Income TTM -278.2m / Total Stockholder Equity 722.7m)
RoCE = -43.67% (Ebit -318.8m / (Equity 722.7m + L.T.Debt 7.26m))
RoIC = -44.11% (NOPAT -318.8m / Invested Capital 722.7m)
WACC = unknown (E(3.02b)/V(3.03b) * Re(8.86%)) + (D(10.2m)/V(3.03b) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 100.00 | Cagr: 1.72%
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -184.5m)
EPS Correlation: 34.59 | EPS CAGR: 89.36% | SUE: 4.0 | # QB: 2
Revenue Correlation: 38.98 | Revenue CAGR: -5.72% | SUE: N/A | # QB: None
Additional Sources for XENE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle